However, the surveillance strategy of combining AFP and ultrasound examinations at 6-month intervals is estimated to detect more than triple the number of patients with operable HCC tumors at the time of diagnosis and reduce almost half the number of deaths from HCC compared with no surveillance (6). This evidence concerns the gene AFP and hepatocellular carcinoma.